Global Leading Market Research Publisher QYResearch announces the release of its latest report *”Medical Radioactive Microspheres – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″*.
For interventional radiologists, oncologists, and healthcare investors, the challenge of treating unresectable solid tumors—particularly primary liver cancer and colorectal cancer liver metastases—has long been constrained by the limitations of conventional therapies. Systemic chemotherapy has significant systemic toxicity and limited efficacy; external beam radiation damages surrounding healthy tissue. The strategic solution lies in medical radioactive microspheres—a type of radioactive embolic agent that uses interventional means to inject micron-sized particles (typically 20–45 microns in diameter) containing radionuclides (such as yttrium-90 [⁹⁰Y]) into the tumor’s blood supply artery. The carrier material is predominantly ceramic, resin, or glass. These microspheres release beta rays targeted to tumors to kill cancer cells at close range while simultaneously embolizing blood vessels, significantly improving local tumor control and reducing normal tissue damage. This report delivers strategic intelligence on market size, radionuclide types, and clinical applications for medical technology decision-makers.
According to Global Info Research, the global market for medical radioactive microspheres was estimated to be worth USD 195 million in 2024 and is forecast to reach USD 403 million by 2031, growing at a compound annual growth rate (CAGR) of 11.2% during the forecast period 2025-2031.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/4763707/medical-radioactive-microspheres
Market Definition & Core Technology Overview
Medical radioactive microspheres are a type of radioactive embolic agent that uses interventional means to inject micron-sized particles (typically 20–45 microns in diameter) containing radionuclides into the tumor’s blood supply artery. The carrier material is predominantly ceramic, resin, or glass. These microspheres release beta rays through targeted tumors to kill tumor cells at close range while simultaneously embolizing blood vessels, which can significantly improve the local control rate of tumors and reduce normal tissue damage.
The therapeutic mechanism, known as Selective Internal Radiation Therapy (SIRT) or Transarterial Radioembolization (TARE), involves:
- Angiography and mapping: A catheter is inserted into the hepatic artery (for liver tumors) and positioned to selectively perfuse the tumor(s). Technetium-99m macroaggregated albumin (⁹⁹ᵐTc-MAA) is injected to assess lung shunting (to prevent radiation pneumonitis) and confirm tumor targeting.
- Microsphere administration: Radioactive microspheres (⁹⁰Y or ¹⁶⁶Ho) are infused through the catheter. The microspheres are preferentially trapped in the tumor microvasculature (tumors are hypervascular, supplied almost exclusively by the hepatic artery, while normal liver parenchyma receives most blood flow from the portal vein).
- Tumor irradiation: The beta-emitting radionuclide delivers high-dose radiation (typically 100–300 Gy) locally to the tumor over several days to weeks (half-life: ⁹⁰Y is 64 hours, ¹⁶⁶Ho is 26.8 hours). Beta particles have a short tissue penetration range (2–10 mm), minimizing damage to adjacent normal structures.
Clinical applications primarily focus on solid tumors that cannot be surgically removed, including:
- Primary liver cancer (hepatocellular carcinoma, HCC) : The most common primary liver malignancy, often diagnosed at an unresectable stage due to underlying cirrhosis.
- Colorectal cancer liver metastases: The liver is the most common site of metastasis from colorectal cancer; radioembolization is used for chemotherapy-refractory disease.
Key advantages of medical radioactive microspheres include high targeting precision (tumor-selective delivery), few systemic side effects (minimal radiation exposure to non-target organs), reliable efficacy (objective response rates of 30–50% in refractory HCC), and the ability to meet individualized treatment needs through customized personalized activity dosing (dosimetry based on tumor volume, liver volume, and lung shunt fraction).
A typical user case (HCC treatment): In December 2025, a 65-year-old patient with unresectable hepatocellular carcinoma (single 8 cm tumor, Child-Pugh A cirrhosis) underwent ⁹⁰Y radioembolization with resin microspheres (Sirtex Medical). Three-month follow-up imaging demonstrated complete response (100% tumor necrosis by mRECIST criteria). The patient experienced mild fatigue and transient transaminitis (grade 1-2) without significant toxicity.
A typical user case (colorectal liver metastases): In January 2026, a 58-year-old patient with chemotherapy-refractory colorectal cancer liver metastases (10+ bilobar metastases, failed three lines of systemic therapy) received ⁹⁰Y glass microspheres (Boston Scientific). Six-month follow-up showed partial response (50% reduction in target lesions) with stable disease for 8 months, extending progression-free survival beyond historical expectations.
Key Industry Characteristics Driving Market Growth
1. Radionuclide Type Segmentation: Yttrium-90 Microspheres Dominate, Holmium-166 Emerging
The report segments the market by radionuclide type:
- Yttrium-90 (⁹⁰Y) Microspheres (Approx. 90–95% of 2024 revenue, dominant segment) : The established standard for radioembolization. ⁹⁰Y is a pure beta emitter (no gamma radiation, simplifying shielding but requiring surrogate imaging for post-treatment verification) with a half-life of 64 hours (suitable for outpatient administration). Two commercial products dominate: Sirtex Medical’s SIR-Spheres (resin microspheres, 20–60 μm, approved for colorectal liver metastases and HCC) and Boston Scientific’s TheraSphere (glass microspheres, 20–30 μm, approved for HCC). ⁹⁰Y microspheres have extensive clinical evidence (multiple prospective trials, real-world registries) and regulatory approval in over 40 countries.
- Holmium-166 (¹⁶⁶Ho) Microspheres (Approx. 5–10% of revenue, fastest-growing segment at 15–16% CAGR) : Emerging alternative with distinct advantages. ¹⁶⁶Ho is a beta emitter (similar to ⁹⁰Y) and gamma emitter (enabling post-treatment SPECT imaging for verification of microsphere distribution, unlike ⁹⁰Y which requires bremsstrahlung imaging). ¹⁶⁶Ho also has paramagnetic properties, enabling MRI-based pretreatment planning and post-treatment verification. Half-life is 26.8 hours (shorter than ⁹⁰Y, potentially reducing isolation requirements). QuiremSpheres (Terumo) is the leading ¹⁶⁶Ho product, approved in Europe but not yet in the US. The segment is growing as clinical evidence accumulates and regulatory approvals expand.
Exclusive industry insight: The distinction between resin microspheres (Sirtex) and glass microspheres (Boston Scientific) is clinically significant despite both using ⁹⁰Y. Resin microspheres have lower activity per sphere (requiring more spheres per administered activity, potentially more uniform distribution) and are approved for colorectal liver metastases and HCC. Glass microspheres have higher activity per sphere (requiring fewer spheres, potentially more focal hot spots) and are approved for HCC (US) and other indications internationally. Physician preference varies by training, institutional experience, and tumor characteristics. The market is not switching between products rapidly; instead, new entrants (Holmium-166, different carrier materials) are expanding the market rather than displacing established products.
2. Application Segmentation: Cancer Treatment Dominates, Diagnosis Emerging
- Cancer Treatment (Approx. 95%+ of 2024 revenue, dominant segment) : Therapeutic use of radioactive microspheres for solid tumors, primarily HCC (60–70% of treatment volume) and colorectal liver metastases (20–25%). Smaller volumes for cholangiocarcinoma, neuroendocrine tumors (NETs), and other liver-dominant metastases. Cancer treatment drives essentially all market revenue.
- Diagnosis (Approx. 1–2% of revenue, niche segment) : Use of radioactive microspheres for dosimetry planning (evaluation of microsphere distribution prior to therapeutic dose) or for imaging of tumor vascularity. This segment is small but growing with the development of diagnostic isotopes (⁹⁹ᵐTc-MAA for lung shunt assessment, ¹⁶⁶Ho for pre-treatment MRI/SPECT).
- Others (Approx. 1–2% of revenue) : Research applications, benign disease treatment (investigational), and combination therapies (radioembolization plus chemotherapy, immunotherapy, or thermal ablation).
3. Regional Dynamics: North America Leads, Asia-Pacific Fastest Growing
North America accounts for approximately 45–50% of global medical radioactive microsphere revenue, driven by the United States (largest market for HCC and colorectal cancer), favorable reimbursement (Medicare, commercial insurance coverage for radioembolization), and presence of key manufacturers (Boston Scientific, Sirtex Medical US operations).
Europe accounts for approximately 25–30% of revenue, led by Germany, France, Italy, Spain, and the United Kingdom. European adoption is supported by clinical guidelines (ESMO, EASL recommending radioembolization for select HCC patients) and reimbursement in major markets.
Asia-Pacific is the fastest-growing region (CAGR 13–14%), driven by China (highest global HCC burden, accounting for approximately 50% of new HCC cases and deaths; regulatory approval for SIR-Spheres and TheraSphere; local manufacturers including Grand Pharmaceutical Group Limited and YH Nu-Med), Japan (established radioembolization practice, favorable reimbursement), South Korea, and Australia.
Future Development Trends
Application field expansion: At present, medical radioactive microspheres are mainly used for liver cancer treatment, but in the future they are expected to be expanded to the treatment of other malignant tumors such as pancreatic cancer, bladder cancer, head and neck cancer, and other solid tumors with arterial supply accessible by catheter. In addition, with the advancement of technology, radioactive microspheres may play a greater role in the treatment of benign diseases.
Technological innovation and product upgrade: The preparation technology of radioactive microspheres will continue to be optimized, such as developing microspheres with smaller particle size and more uniform distribution to improve treatment effect and reduce side effects. At the same time, the research on visualized microspheres (enabling real-time imaging of microsphere distribution during and after administration) will promote the development of real-time monitoring technology, enabling doctors to control the distribution and dosage of microspheres more accurately.
Intensified market competition: As market demand grows, more companies will enter the field of medical radioactive microspheres, and market competition will become more intense. At present, major global manufacturers include Sirtex Medical (now part of Grand Pharmaceutical Group Limited in China) and Boston Scientific Corporation, and more new players may emerge in the future, including Chinese domestic manufacturers developing indigenous products.
Development Drivers
Increasing cancer incidence: The global cancer incidence rate is increasing year by year, especially malignant tumors such as liver cancer. According to the World Health Organization (WHO), liver cancer is the sixth most common cancer globally and the third leading cause of cancer death. As an effective local treatment method for unresectable liver tumors, the market demand for radioactive microspheres will continue to grow.
Technological progress: The preparation technology and application technology of radioactive microspheres are constantly improving. For example, the research and application of yttrium-90 microspheres make treatment more accurate and safe. In addition, the research on visualized microspheres (using isotopes that emit gamma radiation or have paramagnetic properties) will further improve the controllability and effect of treatment.
Policy support: Governments of various countries have continuously increased their support for medical technology, especially in the field of cancer treatment. For example, China has introduced a series of policies to support the development of biopharmaceuticals and medical device industries, and promote the industrialization of technologies such as sustained-release preparations and targeted preparations, including radioactive microspheres.
Development Obstacles
Technical barriers: The preparation technology of medical radioactive microspheres is complex and requires high-precision equipment and processes (reactor irradiation, quality control testing, sterility assurance). At present, domestic companies (outside of established Western manufacturers) still have a certain gap in microsphere preparation technology, relying on imported materials and equipment, which increases production costs and supply chain uncertainty.
Market competition and price pressure: With the intensification of market competition, price pressure will increase. How to reduce production costs and improve market competitiveness while ensuring product quality and efficacy is a challenge faced by companies, particularly new entrants and manufacturers in price-sensitive markets (China, India, Brazil).
Regulation and approval: As medical devices containing radioactive materials, medical radioactive microspheres need to undergo strict regulatory supervision and approval from multiple agencies (FDA in the US, NMPA in China, EMA in Europe, and national nuclear regulatory bodies). Different regulatory requirements in different countries and regions increase the difficulty and time cost of bringing products to market (typically 3–5 years from investigational device exemption to approval).
Exclusive industry insight: The medical radioactive microspheres market is at an inflection point. For a decade, the market was a duopoly (Sirtex SIR-Spheres and Boston Scientific TheraSphere). Recent acquisitions (Grand Pharmaceutical Group Limited’s acquisition of Sirtex in 2018), new entrants (Terumo’s QuiremSpheres for ¹⁶⁶Ho, ABK Biomedical for investigational products), and emerging Chinese domestic manufacturers are fragmenting the market. However, regulatory barriers remain high (nuclear medicine regulations, device approval requirements, reimbursement negotiations). The market is transitioning from a two-player specialty market to a more competitive landscape with geographic segmentation (Western markets dominated by Boston Scientific and Sirtex; China increasingly served by Grand Pharmaceutical and local manufacturers; Europe more open to Holmium-166). For investors and strategists, the highest growth opportunities are in China (unmet need for HCC treatment, local manufacturing, favorable policy environment) and product innovation (visualized microspheres, alternative radionuclides, expanded indications beyond liver tumors).
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
